Department of Gastroenterological and Transplant Surgery Applied Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
J Hepatobiliary Pancreat Sci. 2024 Aug;31(8):528-536. doi: 10.1002/jhbp.12009. Epub 2024 May 26.
Several studies have demonstrated a relationship between genetic polymorphisms of interleukin-1 beta (IL-1β) and cancer development; however, their influence on cancer prognosis is unknown. In the present study, we aimed to evaluate the impact of IL-1β single nucleotide polymorphisms on the hematogenous dissemination and prognosis of hepatocellular carcinoma.
We conducted a retrospective cohort study including patients with hepatocellular carcinoma who underwent primary liver resection at our hospital between April 2015 and December 2018. The primary endpoints were overall and recurrence-free survival. Secondary endpoints were microscopic portal vein invasion and number of circulating tumor cells.
A total of 148 patients were included, 32 with rs16944 A/A genotype. A/A genotype was associated with microscopic portal vein invasion and number of circulating tumor cells (p = .03 and .04). In multivariate analysis, A/A genotype, alpha-fetoprotein level, and number of circulating tumor cells were associated with microscopic portal vein invasion (p = .01, .01, and <.01). A/A genotype, Child-Pugh B, and intraoperative blood loss were independent predictive factors for overall survival (p = .02, <.01, and <.01).
Our results indicate that the IL-1β rs16944 A/A genotype is involved in number of circulating tumor cells, microscopic portal vein invasion, and prognosis in HCC.
多项研究表明白细胞介素-1β(IL-1β)基因多态性与癌症的发生发展有关,但它们对癌症预后的影响尚不清楚。本研究旨在评估 IL-1β 单核苷酸多态性对肝细胞癌血行播散和预后的影响。
我们进行了一项回顾性队列研究,纳入了 2015 年 4 月至 2018 年 12 月在我院接受原发性肝切除术的肝细胞癌患者。主要终点为总生存期和无复发生存期。次要终点为镜下门静脉侵犯和循环肿瘤细胞数。
共纳入 148 例患者,其中 rs16944 A/A 基因型 32 例。A/A 基因型与镜下门静脉侵犯和循环肿瘤细胞数有关(p=0.03 和.04)。多变量分析显示,A/A 基因型、甲胎蛋白水平和循环肿瘤细胞数与镜下门静脉侵犯有关(p=0.01、.01 和 <.01)。A/A 基因型、Child-Pugh B 分级和术中出血量是总生存期的独立预测因素(p=0.02、<.01 和 <.01)。
我们的研究结果表明,IL-1β rs16944 A/A 基因型与 HCC 患者的循环肿瘤细胞数、镜下门静脉侵犯和预后有关。